Learning Objectives:

1. Become familiar with a new class of mineralocorticoid receptor antagonists (MRAs).

2. Become familiar with how a new class of mineralocorticoid receptor antagonists reduces CKD progression.

3. Become familiar with how to use MRAs in order to reduce CV risk and heart failure in high risk patient with kidney disease.

Session date: 
Friday, May 7, 2021 - 12:00pm to 1:00pm
Location: 
Zoom
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
George Bakris, MD